This record contains raw data related to the article: Gender-associated outcomes following percutaneous coronary intervention with a third-generation, ultrathin-strut drug-eluting stent: a real-world, single-center experience. ABSTRACT Introduction. In recent years the new third-generation, ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 µm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). Aim of the present study was to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting. Methods. The present study is a retrospective analysis including all patients treated with BP-SES between January 2017 and December 2019 at a single, high-volume center. Follow-up was performed by outpatient visit or by telephone contact. The main study outcome was target lesion failure (TLF), defined as a composite of cardiovascular death, target vessel myocardial infarction or target lesion revascularization. Results: Overall, 66 (15.9%) female and 349 (84.1%) male patients were included; women were older (median age 70 vs. 66, p=0.003) and with lower BMI (25.0 vs. 26.1, p=0.010) compared to men, with no other relevant differences in baseline characteristics. Indication for percutaneous coronary intervention (PCI) was acute coronary syndrome in 86 (20.7%) of the cases, with no significant differences between male and female patients. A total of 558 lesions were treated with BP-SES stents, 90 in women and 468 in men (1.36 vs. 1.34 lesions per patient, p=0.83); cumulative stent length (33.6 mm vs. 38.4 mm, p=0.078) and mean stent diameter (2.92 mm vs. 3.0 mm, p=0.39) did not differ in women compared to men. Technical and clinical success was achieved in all patients. Stent thrombosis (ST) occurred in 2 (0.5%) patients, both males. TLF occurred in 10 (2.9%) men and in 2 (3.0%) women after a median follow-up of 402 days, without significant differences at log-rank analysis (2.34 events per 100 patient-years in males, 2.53 in females; p=0.80). Conclusions. Ultrathin struts BP-SES showed a safe and effective option for the treatment of CAD in both women and men, with very low ST rate and favorable long-term outcomes